Focus on Oral, Head, Neck & Thyroid Cancers
Swallowing Exercises Shown to Preserve Function in People with Head and Neck Cancer Receiving Radiation
A study from UCLA’s Jonsson Comprehensive Cancer Center has found that people with head and neck cancer receiving radiation as part of their treatment were less likely to experience unwanted side effects such as worsening of diet, need for a feeding tube, or narrowing of the throat passage if they complied with a set of prescribed swallowing exercises during therapy.
The U.S. Food and Drug Administration has expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer. The drug’s new use is intended for patients with locally recurrent or metastatic, progressive differentiated thyroid cancer that no longer responds to radioactive iodine treatment.
The FDA completed review of Cometriq’s application in six months under the agency’s priority review program. This program provides for an expedited six-month review for drugs that may offer major advances in treatment or that provide a treatment when no adequate therapy exists. Cometriq also received orphan-product designation by the FDA because it is intended to treat a rare disease or condition.